SEARCH

SEARCH BY CITATION

References

  • 1
    National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Available at www.nof.org/professionals/NOF_Clinicians_Guide.pdf. Accessed July 27, 2009.
  • 2
    Cosman FA. Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. Endocr Pract. 2009; 15: 483493.
  • 3
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 14341441.
  • 4
    Cosman F. Parathyroid hormone treatment for osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2008; 15: 495501.
  • 5
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18: 19321941.
  • 6
    Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21: 855864.
  • 7
    Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001; 16: 18461853.
  • 8
    Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res. 2007; 22: 149157.
  • 9
    Keaveny TM, Hoffmann PF, Kopperdahl DL. Comparison of the effects of teriparatide and alendronate on parameters of total hip strength as assessed by finite element analysis: results from the Forteo and Alendronate Comparison Trial [abstract]. Presented at the 29th Annual Meeting of the American Society for Bone and Mineral Research; 16–19 September 2007; Honolulu. Abstract 1089.
  • 10
    Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357: 20282039.
  • 11
    Borggrefe J, Graeff C, Nickelsen TN, Marin F, Glüer CC. Quantitative computed tomography assessment of the effects of 24 months of teriparatide treatment on 3-D femoral neck bone distribution, geometry and bone strength: Results from the EUROFORS study. J Bone Miner Res. 2010; 25: 472481. Published online March 18, 2010; DOI: 10.1359/JBMR.090820.
  • 12
    Uusi-Rasi K, Semanick LM, Zanchetta JR, et al. Effects of teriparatide [rhPTH(1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone. 2005; 36: 948958.
  • 13
    McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005; 165: 17621768. (Erratum, Arch Intern Med. 2005; 165:2120).
  • 14
    Black DM, Greenspan SL, Ensrud KE, et al. PaTH Study Investigators 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 349: 12071215.
  • 15
    Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 356: 18091822.
  • 16
    Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997; 350: 550555.
  • 17
    Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001; 16: 925931.
  • 18
    Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R. Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int. 2008; 19: 529535.
  • 19
    Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004; 19: 745751.
  • 20
    Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005; 353: 566575.
  • 21
    Boonen S, Marin F, Obermayer-Pietsch B, et al. EUROFORS Investigators 2008 Effects of previous antiresorptive therapy on the bone mineral density response to 2 years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 93: 852860.
  • 22
    Miller PD, Delmas PD, Lindsay R, et al. Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators 2008 Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 93: 37853793.
  • 23
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003; 349: 12161226.
  • 24
    Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009; 94: 37723780. Published online July 7, 2009; DOI: 10.1210/JC.2008-2719.
  • 25
    Gasser JA, Kneissel M, Thomsen JS, Mosekilde Li. PTH and interactions with bisphosphonates. J Musculoskel Neuron Interact. 2000; 1: 5356.
  • 26
    Gasser JA, Ingold P, Venturiere-Rebmann A, Green JR. Chronic subcutaneous, but not single intravenous, dosing of rats with bisphosphonates results in reduced bone anabolic response to PTH. Paper presented at: American Society for Bone and Mineral Research 28th Annual Meeting; 15–19 September 2006; Philadelphia, Pa. Poster F386;SA386.
  • 27
    Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995; 136: 36323638.
  • 28
    Rosen CJ, Hochberg MC, Bonnick SL, et al. Fosamax Actonel Comparison Trial Investigators 2005 Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res. 2005; 20: 141151.
  • 29
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. Committee of Scientific Advisors of the International Osteoporosis Foundation 2000 The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 11 (suppl 6): S2S17.
  • 30
    Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res. 2004; 19: 330337.
  • 31
    Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000; 85: 231236.
  • 32
    Hasselblad V, Kong DF. Statistical methods for comparison to placebo in active-control trials. Drug Info J. 2001; 35: 435449.
  • 33
    Glover SJ, Gall M, Schoenborn-Kellenberger O, et al. Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from the United Kingdom, France, Belgium and the United States. J Bone Miner Res. 2009; 24: 389397.
  • 34
    Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res. 2007; 22: 495502.
  • 35
    Lindsay R, Cosman F, Zhou H, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res. 2006; 21: 366373.
  • 36
    Burr DB. Does early PTH treatment compromise bone strength? The balance between remodeling, porosity, bone mineral, and bone size. Curr Osteoporos Rep. 2005; 3: 1924.
  • 37
    Uusi-Rasi K, Semanick LM, Zanchetta JR, et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone. 2005; 36: 948958.
  • 38
    Sato M, Westmore M, Ma YL, et al. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res. 2004; 19: 623629.
  • 39
    Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. 2001; 29: 185191.
  • 40
    Ishigaki S. Effect of h-PTH on bone and bone marrow tissue in experimental osteopenia in rat. Nippon Seikeigeka Gakkai Zasshi. 1995; 69: 9921003.
  • 41
    Ikeda T, Sakurai K. Influence of bone marrow fat on the determination of bone mineral content by QCT. Nippon Igaku Hoshasen Gakkai Zasshi. 1994; 54: 886896.
  • 42
    Kuiper JW, van Kuijk C, Grashuis JL, Ederveen AG, Schütte HE. Accuracy and the influence of marrow fat on quantitative CT and dual-energy X-ray absorptiometry measurements of the femoral neck in vitro. Osteoporos Int. 1996; 6: 2530.
  • 43
    Verhaar HJ, Lems WF. PTH-analogs: Comparable or different? Arch Gerontol Geriatr. 2009; 49: e130e132.
  • 44
    Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007; 1117: 209257.